Novel hemocyanin protein adjuvant for animal vaccine market.
Start a new DMP in Loading
Mikota Ltd in collaboration with Cardiff University and Royal Veterinary College (University of London) are evaluating a new protein adjuvant as a vaccine delivery platform, primarily aimed at the companion and livestock market. This project is building on Mikota's earlier hemocyanin work in creating novel constructs to address research demonstrating that companion animals and livestock may be potential asymptomatic COVID-19 carriers. The outputs from this project will demonstrate the efficacy of Mikota's BioCyanin constructs as a vaccine adjuvant in a mouse model. This work will be expanded in future animal trials which are expected to lead to evidence for potential future use in human COVID-19 vaccines, or other coronavirus vaccines.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://beta.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=ukri________::b81b91432eb4e240bd6b4380bf251a26&type=result"></script>');
-->
</script> For further information contact us at helpdesk@openaire.eu